Home » Healthcare » Pharmaceuticals » Neurological Diseases Treatment Market

Neurological Diseases Treatment Market By Indication (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Others) By Drug (Class, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic and Antidepressant, Others) By Route of Administration (Oral, Parenteral, Others) By End Users ( Hospitals, Specialty Clinics, Homecare, Others) By Distribution Channel – Growth, Future Prospects And Competitive Analysis, 2016 – 2028

Summary
Table Of Content

How is the prominence of the neurological disease treatment market?

In the long term, it is anticipated that the market for treating uncommon neurodegenerative diseases would profit from the development in medical tourism and investments in upgrading healthcare facilities throughout the emerging nations of Asia Pacific. In addition, medical technology advancements for detecting and treating various illnesses will support long-term growth. Furthermore, the growing elderly population and the rising frequency of neurological illnesses including Parkinson’s, Alzheimer’s, multiple sclerosis, and others are expected to drive the global market for central nervous system treatments.

What is the Market Size of Neurological disease treatment in terms of value?

Global Neurological Disease Treatment Market is projected to increase at a significant CAGR of XX in the coming years. In 2021, the Global Neurological Disease Treatment Market was valued at USD XX Million and is projected to reach USD XX million by 2028. The demand for neurological disease treatment is projected to increase substantially in the coming years. It is presumed to generate revenue opportunities for the key industry players worth USD XX million during the forecast period between 2022 and 2028.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Interesting Facts about the Neurological disease treatment Industry

An examination of the market for treating rare neurological diseases analyses the major variables influencing current trends and market size, forecast, and technical developments.
The anticipated period will see an absolute monetary potential of more than $5 billion from healthcare spending on Alzheimer’s disease therapy.
Over the projected period, the retail pharmacy and drug store business is anticipated to grow while maintaining high client satisfaction standards.
North America controls 40% of the global market for rare neurological disease treatments in terms of revenue.
Various treatments used to treat various neurological illnesses are discussed, the innovative pipeline, the patent expiration of blockbuster drugs, and new medication approvals.
Companies in the neurological disorder medicines industry are implementing new therapeutic methods for treating Parkinson’s disease.

Who are the Top 10 players/companies in the neurological disease treatment market in terms of value?

The key players in the global neurological disease treatment market in terms of value include Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India). In September 2021 Four psychiatric and neurology chemicals, including ulotaront, are the subject of a licensing deal between Otsuka and Sumitomo Dainippon Pharma. As per the agreement, Sunovion and Otsuka will equally divide the expenses and income from clinical studies, regulatory filings, and commercialization in each of these countries and regions. After further conversations between Sumitomo Dainippon Pharma Group and Otsuka, additional ulotaront indications will be discovered. The U.S. FDA gave Johnson & Johnson permission to introduce Ponvory as a daily oral medication for the treatment of multiple sclerosis.

Who are the Top 10 Countries in the Neurological Disease Treatment Market?

In the global neurological disease treatment market, the major countries are China, India, the U.S., Canada, the U.K., Germany, France, Russia, Belgium, Netherlands, and Norway. For each regional market, a country-specific assessment of the demand for treatments for rare neurological diseases has been provided, along with estimates of market size and forecast price points, price indices, and the effects of significant regional and national dynamics. These estimates were compiled using quotes from many suppliers, manufacturers, experts, and manufacturers of treatments for rare neurological diseases. On all of the regional markets that were included in the research, growth estimates were also provided. In addition, the research provides answers to questions about potential market trends, development prospects, and other possibilities.

Which is the major drug class in the Neurological disease treatment Market?

The major drug class of neurological disease treatment includes Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anticholinergic, Antiepileptic, Antipsychotic and Antidepressant, and others. Together, anticholinergic and antiepileptic medications accounted for around 42% of the market. Rising neurological illness prevalence, ongoing advancements in diagnostic technology, and increased knowledge of early disease detection due to awareness programs run by governmental or non-governmental organizations are the main reasons fueling the growth of these two market sectors. The market launch of effective pharmaceuticals in the near future, however, due to a robust drug pipeline, is anticipated to alter the market share of conventional drug therapies and further accelerate this market’s expansion.

What are the Major Driving Factors for the Neurological disease treatment Market?

The growing cost of healthcare, which helps to improve its infrastructure, is a crucial element affecting the market’s growth rate for dermatitis. Different government organizations’ efforts to strengthen the healthcare infrastructure by boosting financing will further impact the market dynamics. The market is also expanding since more new medications are being developed. This would present advantageous chances for the expansion of the market. Neurological disorders and brain traumas are among the leading causes of death in the globe. As a result, scientists are looking for ways to develop novel drugs that, by modifying glucose metabolism, might enhance the treatment of neurological illnesses.

What are the Major Restraints for the Neurological disease treatment Market?

The key restraint of the global neurological disease treatment market, which is projected to hamper the market growth, include the high cost of research and development operations, which would impede the market’s rate of expansion. In addition, the market for medications for neurological disorders will face difficulties due to the absence of healthcare infrastructure in developing countries and a shortage of qualified personnel. Furthermore, during the projection period, product recalls, and stringent government restrictions would serve as restraints and further hinder the market’s development pace.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Which Region Dominated the World Neurological Disease Treatment Market?

In terms of market share and revenue, North America now dominates the market for medications for neurological disorders, and this dominance is expected to grow over the projected period. This is because neurological disorders are very common in this area, and growing healthcare costs will further accelerate market expansion. The market’s growth rate in this area will also be boosted by the expanding presence of major important players and the rise in the number of FDA-approved pharmaceuticals. Because there are so many generic manufacturers in Asia-Pacific, the area is predicted to increase between 2022 and 2029. Additionally, expanding the healthcare sector’s infrastructure and growing government efforts will accelerate the market’s expansion in this area. The rising occurrence of such uncommon neurological illnesses in the region has been one of the main drivers of the North American market’s expansion. Around 200,000 people in the US alone are affected by uncommon neurological disorders, according to research from the Center for Rare Neurological Disease Research. Additionally, it is anticipated that rising healthcare spending and the availability of a developed and well-established healthcare infrastructure would support the growth of the North American area.

Segmentation of Global Neurological Disease Treatment Market-

Global Neurological Disease Treatment Market – By Indication

Epilepsy
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Cerebrovascular Disease
Others

Global Neurological Disease Treatment Market – By Drug Class

Cholinesterase Inhibitors
NMDA Receptor Antagonists
Antiepileptic
Antipsychotic and Antidepressant
Others

Global Neurological Disease Treatment Market – By Route of Administration

Oral
Parenteral
Others

Global Neurological Disease Treatment Market – By End Users

Hospitals
Specialty Clinics
Homecare
Others

Global Neurological Disease Treatment Market – By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Neurological Disease Treatment Market

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Neurological Disease Treatment Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Indication
3.3.2. Route of Administration
3.3.3. Drug Class
3.3.4. End Users
3.3.5. Geography
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Indications
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis

4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Top 6 Players
4.3. Top 3 Players
4.4. Major Strategies Adopted by Key Players

5. COVID 19 Impact Analysis 5.1. Global Neurological Disease Treatment Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply

6. North America
6.1. North America Neurological Disease Treatment Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Epilepsy
6.2.3. Alzheimer’s Disease
6.2.4. Parkinson’s Disease
6.2.5. Multiple Sclerosis
6.2.6. Cerebrovascular Disease
6.2.7. Others
6.3. North America Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. Oral
6.3.3. Parenteral
6.3.4. Others
6.4. North America Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
6.4.1. Overview
6.4.2. Cholinesterase Inhibitors
6.4.3. NMDA Receptor Antagonists
6.4.4. Antiepileptic
6.4.5. Antipsychotic and Antidepressant
6.5. North America Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
6.5.1. Overview
6.5.2. Hospitals
6.5.3. Specialty Clinics
6.5.4. Homecare
6.5.5. Others
6.6. North America Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
6.6.1. Overview
6.6.2. Online
6.6.3. Hospital Pharmacy
6.6.4. Pharmacies/Drug Stores
6.6.5. Other offline channels

7. Europe
7.1. Europe Neurological Disease Treatment Market, by Country, 2016-2028(US$ Bn)
7.1.1. UK
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Ukraine
7.1.7. Spain
7.1.8. Belgium
7.1.9. Netherland
7.1.10. Austria
7.1.11. Sweden
7.1.12. Poland
7.1.13. Denmark
7.1.14. Switzerland
7.1.15. Rest of Europe
7.2. Europe Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Epilepsy
7.2.3. Alzheimer’s Disease
7.2.4. Parkinson’s Disease
7.2.5. Multiple Sclerosis
7.2.6. Cerebrovascular Disease
7.2.7. Others
7.3. Europe Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Oral
7.3.3. Parenteral
7.3.4. Others
7.4. Europe Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
7.4.1. Overview
7.4.2. Cholinesterase Inhibitors
7.4.3. NMDA Receptor Antagonists
7.4.4. Antiepileptic
7.4.5. Antipsychotic and Antidepressant
7.5. Europe Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
7.5.1. Overview
7.5.2. Hospitals
7.5.3. Specialty Clinics
7.5.4. Homecare
7.5.5. Others
7.6. Europe Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
7.6.1. Overview
7.6.2. Online
7.6.3. Hospital Pharmacy
7.6.4. Pharmacies/Drug Stores
7.6.5. Other offline channels

8. Asia Pacific
8.1. Asia Pacific Neurological Disease Treatment Market, by Country, 2016-2028(US$ Bn)
8.1.1. China
8.1.2. Japan
8.1.3. South Korea
8.1.4. India
8.1.5. Australia
8.1.6. New Zealand
8.1.7. Taiwan
8.1.8. Indonesia
8.1.9. Malaysia
8.1.10. Philippine
8.1.11. Rest of Asia Pacific
8.2. Asia Pacific Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. Epilepsy
8.2.3. Alzheimer’s Disease
8.2.4. Parkinson’s Disease
8.2.5. Multiple Sclerosis
8.2.6. Cerebrovascular Disease
8.2.7. Others
8.3. Asia Pacific Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. Oral
8.3.3. Parenteral
8.3.4. Others
8.4. Asia Pacific Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
8.4.1. Overview
8.4.2. Cholinesterase Inhibitors
8.4.3. NMDA Receptor Antagonists
8.4.4. Antiepileptic
8.4.5. Antipsychotic and Antidepressant
8.5. Asia Pacific Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
8.5.1. Overview
8.5.2. Hospitals
8.5.3. Specialty Clinics
8.5.4. Homecare
8.5.5. Others
8.6. Asia Pacific Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
8.6.1. Overview
8.6.2. Online
8.6.3. Hospital Pharmacy
8.6.4. Pharmacies/Drug Stores
8.6.5. Other offline channels

9. Latin America
9.1. Latin America Neurological Disease Treatment Market, by Country, 2016-2028(US$ Bn)
9.1.1. Brazil
9.1.2. Argentina
9.1.3. Peru
9.1.4. Chile
9.1.5. Colombia
9.1.6. Rest of Latin America
9.2. Latin America Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. Epilepsy
9.2.3. Alzheimer’s Disease
9.2.4. Parkinson’s Disease
9.2.5. Multiple Sclerosis
9.2.6. Cerebrovascular Disease
9.2.7. Others
9.3. Latin America Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. Oral
9.3.3. Parenteral
9.3.4. Others
9.4. Latin America Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
9.4.1. Overview
9.4.2. Cholinesterase Inhibitors
9.4.3. NMDA Receptor Antagonists
9.4.4. Antiepileptic
9.4.5. Antipsychotic and Antidepressant
9.5. Latin America Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
9.5.1. Overview
9.5.2. Hospitals
9.5.3. Specialty Clinics
9.5.4. Homecare
9.5.5. Others
9.6. Latin America Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
9.6.1. Overview
9.6.2. Online
9.6.3. Hospital Pharmacy
9.6.4. Pharmacies/Drug Stores
9.6.5. Other offline channels

10. Middle East
10.1. Middle East Neurological Disease Treatment Market, by Country, 2016-2028(US$ Bn)
10.1.1. UAE
10.1.2. KSA
10.1.3. Israel
10.1.4. Turkey
10.1.5. Iran
10.1.6. Rest of Middle East
10.2. Middle East Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. Epilepsy
10.2.3. Alzheimer’s Disease
10.2.4. Parkinson’s Disease
10.2.5. Multiple Sclerosis
10.2.6. Cerebrovascular Disease
10.2.7. Others
10.3. Middle East Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. Oral
10.3.3. Parenteral
10.3.4. Others
10.4. Middle East Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
10.4.1. Overview
10.4.2. Cholinesterase Inhibitors
10.4.3. NMDA Receptor Antagonists
10.4.4. Antiepileptic
10.4.5. Antipsychotic and Antidepressant
10.5. Middle East Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
10.5.1. Overview
10.5.2. Hospitals
10.5.3. Specialty Clinics
10.5.4. Homecare
10.5.5. Others
10.6. Middle East Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
10.6.1. Overview
10.6.2. Online
10.6.3. Hospital Pharmacy
10.6.4. Pharmacies/Drug Stores
10.6.5. Other offline channels

11. Africa
11.1. Africa Neurological Disease Treatment Market, by Country, 2016-2028(US$ Bn)
11.1.1. South Africa
11.1.2. Egypt
11.1.3. Nigeria
11.1.4. Rest of Africa
11.2. Africa Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. Epilepsy
11.2.3. Alzheimer’s Disease
11.2.4. Parkinson’s Disease
11.2.5. Multiple Sclerosis
11.2.6. Cerebrovascular Disease
11.2.7. Others
11.3. Africa Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. Oral
11.3.3. Parenteral
11.3.4. Others
11.4. Africa Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
11.4.1. Overview
11.4.2. Cholinesterase Inhibitors
11.4.3. NMDA Receptor Antagonists
11.4.4. Antiepileptic
11.4.5. Antipsychotic and Antidepressant
11.5. Africa Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
11.5.1. Overview
11.5.2. Hospitals
11.5.3. Specialty Clinics
11.5.4. Homecare
11.5.5. Others
11.6. Africa Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
11.6.1. Overview
11.6.2. Online
11.6.3. Hospital Pharmacy
11.6.4. Pharmacies/Drug Stores
11.6.5. Other offline channels

12. Global
12.1. Global Neurological Disease Treatment Market, by Indication, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. Epilepsy
12.1.3. Alzheimer’s Disease
12.1.4. Parkinson’s Disease
12.1.5. Multiple Sclerosis
12.1.6. Cerebrovascular Disease
12.1.7. Others
12.2. Global Neurological Disease Treatment Market, by Route of Administration, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. Oral
12.2.3. Parenteral
12.2.4. Others
12.3. Global Neurological Disease Treatment Market, by Drug Class, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. Cholinesterase Inhibitors
12.3.3. NMDA Receptor Antagonists
12.3.4. Antiepileptic
12.3.5. Antipsychotic and Antidepressant
12.4. Global Neurological Disease Treatment Market, by End Users, 2016-2028(US$ Bn)
12.4.1. Overview
12.4.2. Hospitals
12.4.3. Specialty Clinics
12.4.4. Homecare
12.4.5. Others
12.5. Global Neurological Disease Treatment Market, by Sales Channel, 2016-2028(US$ Bn)
12.5.1. Overview
12.5.2. Online
12.5.3. Hospital Pharmacy
12.5.4. Pharmacies/Drug Stores
12.5.5. Other offline channels

13. Company Profiles
13.1. Cipla Inc.
13.2. Merck KGaA
13.3. Eisai Co., Ltd.
13.4. AstraZeneca
13.5. Sanofi
13.6. Novartis AG
13.7. Abbott
13.8. Pfizer Inc.
13.9. GSK
13.10. WOCKHARDT
13.11. Novo Nordisk A/S
13.12. F. Hoffmann-La Roche Ltd.
13.13. Teva Pharmaceutical
13.14. Glenmark Pharmaceuticals Limited
13.15. Bausch Health Companies Inc.
13.16. Otsuka America Pharmaceutical, Inc.
13.17. Johnson & Johnson Private Limited
13.18. Takeda Pharmaceutical Company Limited
13.19. Sumitomo Corporation
13.20. Biocon
13.21. Others

List of Figurers

FIG. 1 Global Neurological Disease Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Neurological Disease Treatment Market Segmentation
FIG. 4 Global Neurological Disease Treatment Market, by Indication, 2019 (US$ Bn)
FIG. 5 Global Neurological Disease Treatment Market, by Route of Administration, 2021 (US$ Bn)
FIG. 6 Global Neurological Disease Treatment Market, by Geography, 2021 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Geography, 2021
FIG. 8 Global Market Positioning of Key Neurological Disease Treatment Market Manufacturers, 2019
FIG. 9 Global Neurological Disease Treatment Market Value Contribution, By Indication, 2021 & 2028 (Value %)
FIG. 10 Global Neurological Disease Treatment Market, by Epilepsy, Value, 2016-2028 (US$ Bn)
FIG. 11 Global Neurological Disease Treatment Market, by Alzheimer’s Disease, Value, 2016-2028 (US$ Bn)
FIG. 12 Global Neurological Disease Treatment Market, by Parkinson’s Disease, Value, 2016-2028 (US$ Bn)
FIG. 13 Global Neurological Disease Treatment Market, by Multiple Sclerosis, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Neurological Disease Treatment Market, by Cerebrovascular Disease, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Neurological Disease Treatment Market Value Contribution, By Route of Administration, 2021 & 2028 (Value %)
FIG. 16 Global Neurological Disease Treatment Market, by Oral, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Neurological Disease Treatment Market, by Parenteral, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Neurological Disease Treatment Market Value Contribution, By Drug Class, 2021 & 2028 (Value %)
FIG. 19 Global Neurological Disease Treatment Market, by Cholinesterase Inhibitors, 2016-2028 (US$ Bn)
FIG. 20 Global Neurological Disease Treatment Market, by NMDA Receptor Antagonists, Value, 2016-2028 (US$ Bn)
FIG. 21 Global Neurological Disease Treatment Market, by Antiepileptic, Value, 2016-2028 (US$ Bn)
FIG. 22 Global Neurological Disease Treatment Market, by Antipsychotic and Antidepressant, Value, 2016-2028 (US$ Bn)
FIG. 23 Global Neurological Disease Treatment Market Value Contribution, By End Users, 2021 & 2028 (Value %)
FIG. 24 Global Neurological Disease Treatment Market, by Hospitals, 2016-2028 (US$ Bn)
FIG. 25 Global Neurological Disease Treatment Market, by Specialty Clinics, 2016-2028 (US$ Bn)
FIG. 26 Global Neurological Disease Treatment Market, by Homecare, 2016-2028 (US$ Bn)
FIG. 27 Global Neurological Disease Treatment Market Value Contribution, By Sales Channel, 2021 & 2028 (Value %)
FIG. 28 Global Neurological Disease Treatment Market, by Online, 2016-2028 (US$ Bn)
FIG. 29 Global Neurological Disease Treatment Market, by Hospital Pharmacy, 2016-2028 (US$ Bn)
FIG. 30 Global Neurological Disease Treatment Market, by Pharmacies/Drug Stores, 2016-2028 (US$ Bn)
FIG. 31 Global Neurological Disease Treatment Market, by Other offline channels, 2016-2028 (US$ Bn)
FIG. 32 U.S. Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 33 Rest of North America Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 34 U.K. Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 35 Germany Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 36 France Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 37 Italy Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 38 Spain Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 39 Russia Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 40 BENELUX Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 41 Poland Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 42 Austria Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 43 Rest of Europe Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 44 Japan Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 45 China Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 46 India Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 47 South Korea Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 48 Australia Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 49 Southeast Asia Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 50 Rest of Asia Pacific Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 51 Middle East & Africa Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 52 South Africa Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 53 Nigeria Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 54 Egypt Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 55 GCC Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 56 Israel Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 57 Latin America Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 58 Mechanicalzil Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 59 Argentina Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 60 Colombia Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 61 Peru Neurological Disease Treatment Market, 2016-2028 (US$ Bn)
FIG. 62 Chile Neurological Disease Treatment Market, 2016-2028 (US$ Bn)

List of Table

TABLE 1 Market Snapshot: Global Neurological Disease Treatment Market
TABLE 2 Global Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 3 Global Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 4 Global Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 5 Global Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 6 Global Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 7 Global Neurological Disease Treatment Market, by Geography, 2016-2028 (US$ Bn)
TABLE 8 North America Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 9 North America Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 10 North America Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 11 North America Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 12 North America Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 13 North America Neurological Disease Treatment Market, by Country, 2016-2028 (US$ Bn)
TABLE 14 Europe Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 15 Europe Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 16 Europe Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 17 Europe Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 18 Europe Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 19 Europe Neurological Disease Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 20 Asia Pacific Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 21 Asia Pacific Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 22 Asia Pacific Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 23 Asia Pacific Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 24 Asia Pacific Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 25 Asia Pacific Neurological Disease Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 26 Latin America Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 27 Latin America Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 28 Latin America Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 29 Latin America Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 30 Latin America Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 31 Latin America Neurological Disease Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 32 Middle East Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 33 Middle East Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 34 Middle East Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 35 Middle East Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 36 Middle East Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 37 Middle East Neurological Disease Treatment Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 38 Africa Neurological Disease Treatment Market, by Indication, 2016-2028 (US$ Bn)
TABLE 39 Africa Neurological Disease Treatment Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 40 Africa Neurological Disease Treatment Market, by Drug Class, 2016-2028 (US$ Bn)
TABLE 41 Africa Neurological Disease Treatment Market, by Consumer, 2016-2028 (US$ Bn)
TABLE 42 Africa Neurological Disease Treatment Market, by Sales Channel, 2016-2028 (US$ Bn)
TABLE 43 Africa Neurological Disease Treatment Market, by Country/Region, 2016-2028 (US$ Bn)

Frequently Asked Questions:

Which is the leading market for neurological disease treatment?

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the high presence of generic manufacturers in this region. Additionally, expanding the healthcare sector’s infrastructure and growing government efforts will accelerate the market’s expansion in this area.

What are the key drivers for the growth of the neurological disease treatment market?

The growing cost of healthcare contributes to the development of the market for dermatitis and has a significant impact on its growth rate. Different government organizations’ efforts to strengthen the healthcare infrastructure by boosting financing will further impact the market dynamics.

Which is the major segment in the neurological disease treatment Market by Indication?

Together, epilepsy, Alzheimer’s disease, and Parkinson’s disease accounted for of the market share because of these diseases’ rising prevalence, the development of novel diagnostic tools for neurological conditions, and the expansion of awareness campaigns run by both governmental and non-governmental organizations.

Which is the major segment in the Neurological disease treatment Market by distribution channel?

Based on the distribution channel, the hospital pharmacy category was able to grasp the global increasing preference for hospital-based therapy and more substantial sales revenue.

Who are the major players in this market?

Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –